Ensartinib
Ensacove · ALK TKI
ALK TKI carrying the crizotinib-class renal signature: benign creatinine rise and possible renal cysts.
Xalkori · CRIZ
ALK/ROS1/MET TKI · approved 2011 · 10 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An ALK/ROS1/MET inhibitor notable for reversible creatinine rises and the development or growth of complex renal cysts.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Crizotinib commonly causes a reversible rise in serum creatinine and is distinctively associated with renal cysts: in the Halpenny series, new or enlarging cysts in 16% (9 of 57 serially imaged patients) and frankly complex cysts in 4% (2 of 57) — the 16% headline is the any-cyst rate, not a complex-cyst or AKI rate. Peripheral edema and electrolyte disturbances (including hypophosphatemia and hypokalemia) are reported. In real-world ALK-inhibitor cohorts, creatinine-based AKI/CKD events are frequent but mostly mild and reversible; frank kidney failure is uncommon.Source: Halpenny et al., Lung Cancer 2017 (renal cysts 16%); Izzedine et al., Invest New Drugs 2016
Creatinine rises within weeks (reversible on stopping), while the renal cysts develop and enlarge over months.
Distilled from: “Creatinine rise often within weeks and reverses on discontinuation; cysts develop and grow over months.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal cyst formation or growth in 16% of crizotinib-treated NSCLC; complex cysts ~4% (retrospective CT cohort)
Median eGFR fell ~15% by week 2 (creatinine-secretion effect, not true nephrotoxicity); 12.6% shifted to eGFR <45, largely reversible on discontinuation
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Representative incidence
Renal Cysts strikes: Distal Tubule / Collecting Duct.
Renal Cysts
Drug-induced complex renal cysts — the distinctive ALK-inhibitor lesion, classically crizotinib. Usually asymptomatic, dose/duration-related, and they tend to regress when the drug is stopped.
Multitargeted ATP-competitive inhibitor of ALK, ROS1, and MET tyrosine kinases. Used in ALK-positive and ROS1-positive non-small-cell lung cancer.
Class-level context for the major non-renal toxicities of the ALK/ROS1/MET TKI class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Increased exposure to crizotinib occurred in patients with pre-existing severe renal impairment (CL cr less than 30 mL/min calculated using the modified Cockcroft-Gault equation for adult patients and the Schwartz equation for pediatric patients) not requiring dialysis, therefore reduce dosage of XALKORI in these patients [see Dosage and Administration (2.8) , Clinical Pharmacology (12.3) ] . No dose adjustment is recommended in patients with mild to moderate renal impairment (CL cr 30 to 89 mL/min).
Kidney rows of the label's dosage tables
From the Xalkori label (Oct 2026) · DailyMed
No row of this label's 8 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 10,760 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
3,414 of 10,760 reports
Reported with hospitalization
2,674 of 10,760 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 914 of the 10,760 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Crizotinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Ensacove · ALK TKI
ALK TKI carrying the crizotinib-class renal signature: benign creatinine rise and possible renal cysts.
Vitrakvi · TRK inhibitor
Mild creatinine rise; generally well tolerated.
Rozlytrek · TRK/ROS1 TKI
Creatinine rise via reduced tubular secretion.
Augtyro · ROS1/TRK TKI
2023 ROS1 inhibitor; creatinine rise via secretion block.
Ibtrozi · ROS1 TKI
Next-gen ROS1 TKI; benign transporter-mediated creatinine rise (pseudo-AKI), not true GFR loss.
Tabrecta · MET inhibitor
Reversible creatinine rise and edema.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Crizotinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Crizotinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 32 clinical records among all 35 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.